Stryker Co. (NYSE:SYK) Shares Purchased by Allen Mooney & Barnes Investment Advisors LLC

Allen Mooney & Barnes Investment Advisors LLC boosted its holdings in Stryker Co. (NYSE:SYK) by 13.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,535 shares of the medical technology company’s stock after acquiring an additional 182 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Stryker were worth $554,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SYK. Chicago Partners Investment Group LLC grew its stake in shares of Stryker by 12.0% in the fourth quarter. Chicago Partners Investment Group LLC now owns 2,447 shares of the medical technology company’s stock valued at $753,000 after buying an additional 263 shares in the last quarter. Virtu Financial LLC purchased a new stake in Stryker in the fourth quarter valued at $748,000. Integrated Advisors Network LLC lifted its holdings in shares of Stryker by 10.6% in the 4th quarter. Integrated Advisors Network LLC now owns 3,342 shares of the medical technology company’s stock valued at $1,001,000 after purchasing an additional 321 shares during the last quarter. Centaurus Financial Inc. boosted its holdings in shares of Stryker by 10.9% in the fourth quarter. Centaurus Financial Inc. now owns 878 shares of the medical technology company’s stock valued at $263,000 after acquiring an additional 86 shares during the period. Finally, Richardson Financial Services Inc. purchased a new position in Stryker during the 4th quarter worth $121,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 220,068 shares of company stock valued at $71,811,372 over the last three months. 5.90% of the stock is owned by insiders.

Analyst Ratings Changes

SYK has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Royal Bank of Canada restated an “outperform” rating and issued a $386.00 price target on shares of Stryker in a report on Wednesday, July 31st. Wolfe Research assumed coverage on shares of Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 target price for the company. Piper Sandler reissued an “overweight” rating and set a $380.00 price target on shares of Stryker in a research report on Tuesday, September 10th. Finally, Truist Financial boosted their price objective on shares of Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $381.16.

Stryker Trading Up 1.2 %

Shares of SYK opened at $359.71 on Tuesday. The stock has a market cap of $137.03 billion, a PE ratio of 41.06, a P/E/G ratio of 2.73 and a beta of 0.91. Stryker Co. has a 12 month low of $255.22 and a 12 month high of $374.63. The stock’s 50-day moving average is $352.72 and its two-hundred day moving average is $342.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same period in the prior year, the company posted $2.54 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities analysts forecast that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio is currently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.